Get to know our clinical trials
Clinical trial to evaluate the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with acute myeloid leukemia and mutated TP53
THE PRIMARY OBJECTIVE OF THE PRESENT STUDY IS TO COMPARE THE EFFICACY OF MAGROLIMAB AZACITIDINE VERSUS VENETOCLAX AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) WHO ARE SUITABLE FOR NON-INTENSIVE THERAPY, AS DETERMINED BY OVERALL SURVIVAL (OS).
Technical Summary
- Code EudraCT: 2020-003949-11
- Protocol number: GS-US-546-5857
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.